English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Background Both inflammation and angiogenesis contribute to the progression of abdominal aortic aneurysm (AAA) disease. RGD is a peptide binder of the avb3 integrin, which is expressed highly on activated macrophages and angiogenic endothelial cells. Human ferritin (HFn) is a nanoscale protein cage with 12nm diameter and 8nm interior cavity, which we have utilized as a platform for molecular/cellular imaging. We can genetically introduce RGD peptide to HFn. The purpose of this study is to evaluate RGD-conjugated HFn iron oxide nanoparticles for enhanced in vivo MRI of murine AAAs.

RGD targeting of human ferritin iron-oxide nanoparticles enhances in vivo molecular MRI of experimental aortic aneurysms